AdipoPharma restores the normal function of the adipocyte for the treatment of insulin resistance, type 2 diabetes, and related metabolic disorders. AdipoPharma SAS is headquartered in Strasbourg, ...

Significant technical improvement in single-nucleus RNA-seq reveals distinct adipocyte subpopulations that respond differently to obesity, including those undergoing adaptive healthy expansion and ...

Adipocyte-specific GSK3β (glycogen synthase kinase-3 beta) deficiency reduces obesity-associated adipose tissue inflammation, increases OxPhos complexes, and decreases adipocyte size.

Adipose tissue is an active endocrine organ. An increased fat cell size is manifested by metabolic dysfunction, insulin resistance, dyslipidemia, and abnormal adipokine secretion. Ordinary cytological ...

The size of adipocytes varies among fat depots of different anatomic regions, indicative of the significant fluctuation of lipid store and other cellular functions. The most volume of the white fat ...

Adipose tissue expands by increasing the total adipocyte number (hyperplasia) and adipocyte size (hypertrophy). The ability of adipose tissue to expand and reduce its mass in response to energy intake ...

Male and female mice harboring adipocyte-specific deletion of both STAT5 genes (STAT5 AKO) exhibit increased subcutaneous or inguinal adipose tissue mass, but no changes in visceral or gonadal fat ...

Anatomical location and genetics largely determine the proportional increase in adipocyte size and number and the physiological responses.

During obesity‐driven adipose tissue remodeling, the increase in the number and size of adipocytes means further tissue expansion is limited by the tight ECM framework, which subsequently undergoes ...

The size of subcutaneous, but not visceral, fat depots is dependent on the number of embryonic adipocyte progenitors.